Medtronic stock: FDA clears Hugo for general surgery
Published on 11/20/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHugo expands its surgical reach
- FDA clearance extends Hugo into a broad range of U.S. general surgery procedures.
- Medtronic expects more than 50,000 Hugo procedures by the end of its fiscal year.
- The company is scheduled to report fiscal second-quarter results on November 24.
Medtronic plc said on Nov. 17 that the U.S. Food and Drug Administration had cleared its Hugo robotic-assisted surgery system for general surgery procedures. The company described the decision in a PR Newswire release.
Hugo reaches general surgery
The expanded U.S. 510(k) clearance covers upper-abdominal procedures including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. It also covers lower-abdominal inguinal hernia procedures and appendectomy.
Medtronic said the cleared procedures represent about 3.5 million surgeries annually in the United States, or more than half of the country's soft-tissue procedures. The decision broadens Hugo beyond its earlier urology focus and gives hospitals access to a modular system that can use only the robotic arms required for a procedure.
Procedure growth remains the key signal
The company said global Hugo procedure growth is running at more than twice the robotic-surgery market and is on track to surpass 50,000 procedures by the end of Medtronic's fiscal year. General surgery is also the fastest-growing area for Hugo outside the United States, ahead of urology and gynecology, according to Medtronic.
For investors, the clearance expands the commercial addressable market for a product already in clinical use at hospitals and health systems. Revenue conversion will depend on hospital adoption, procedure volumes and the pace at which surgical teams add the platform to their workflows.
Medtronic stock and next catalyst
Medtronic stock traded at 92.27 euros on Lang & Schwarz at 17:42 CET on Friday, Nov. 20, 0.18 percent below the Xetra close of Friday, Nov. 20. The next scheduled company catalyst is Medtronic's fiscal second-quarter earnings report on Nov. 24.
Medtronic plc at a glance
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT on the New York Stock Exchange
- Lang & Schwarz: 92.27 euros at 17:42 CET on Nov. 20, 2026
- Xetra close: 92.44 euros on Nov. 20, 2026
Broader market trading is covered in Current market reports.
